|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer显示文摘AIM: To investigate the prognostic role of KRAS and BRAF mutations after adjustment for microsatellite instability(MSI) status in Japanese colorectal cancer(CRC) population.METHODS: We assessed KRAS and BRAF mutations and MSI status in 813 Japanese patients with curatively resected, stage Ⅰ-Ⅲ CRC and examined associations of these mutations with disease-free survival(DFS) and overall survival(OS) using uni- and multivariate Cox proportional hazards models.RESULTS: KRAS and BRAF mutations were detected in 312(38%) of 812 and 40(5%) of 811 tumors, respectively. KRAS mutations occurred more frequently in females than in males(P = 0.02), while the presence of BRAF mutations was significantly associated with the female gender(P = 0.006), proximal tumor location(P < 0.001), mucinous or poorly differentiated histology(P < 0.001), and MSI-high tumors(P < 0.001). After adjusting for relevant variables, including MSI status, KRAS mutations were associated with poorer DFS(HR = 1.35; 95%CI: 1.03-1.75) and OS(HR = 1.46; 95%CI: 1.09-1.97). BRAF mutations were poor prognostic factors for DFS(HR = 2.20; 95%CI: 1.19-4.06) and OS(HR = 2.30; 95%CI: 1.15-4.71). Neither the BRAF by MSI interaction test nor the KRAS by MSI interaction test yielded statistically significant results for DFS and OS.CONCLUSION: KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, inJapanese patients with curatively resected CRC. | Shigenori Kadowaki Miho Kakuta Shuhei Takahashi Akemi Takahashi Yoshiko Arai Yoji Nishimura Toshimasa Yatsuoka Akira Ooki Kensei Yamaguchi Keitaro Matsuo Kei Muro Kiwamu Akagi | 2015 | World Journal of Gastroenterology2015，21，4： | 14 |
| 2 | Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis显示文摘A 69-year-old man was admitted to our hospital in October 2003,for further examination of two liver tumors.He was diagnosed with hepatocellular carcinoma(HCC) arising from decompensated hepatitis B virus(HBV)-related cirrhosis.Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC.His Child-Pugh score was 9 points at start of lamivudine treatment,improving to 5 points after 1 year.His indocyanine green at 15 min after injection test score was 48%before lamivudine treat-ment,improving to 22%after 2 years and to 5%after 4 years.Radiofrequency ablation controlled the HCC foci and maintained his liver function.In April 2009,abdominal computed tomography revealed a tumor thrombus in the right portal vein.Since his indocyanine green test results had improved to less than 10%,we performed a right hepatectomy,which was successful.To our knowledge,there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis.The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC. | Koichi Honda Masataka Seike Shin-ichiro Maehara Koichiro Tahara Hideaki Anai Akira Moriuchi Toyokichi Muro | 2012 | World Journal of Gastroenterology2012，18，20： | 7 |
| 3 | Immunogenetic biomarkers in inflammatory bowel diseases:Role of the IBD3 region显示文摘Many studies have demonstrated the linkage between the IBD3 region(6p21.1-23),an area which encompasses the famous human leukocyte antigen(HLA) complex,and Crohn's disease(CD) or ulcerative colitis(UC).IBD3 is the only region that meets genome-wide significance,and provides stronger evidence of the linkage than 16p13.1-16q12.2(IBD1),the locus that contains the susceptibility gene CARD15.However,despite these findings,IBD3 susceptibility genes remain elusive and unclear due to the strong linkage disequilibrium,extensive polymorphism,and high gene density that characterize this area and also due to varying allele frequencies in populations around the world.This area presents an extremely high abundance of genes,including the classical and non-classical major histocompatibility complex(MHC) class Ⅰ and Ⅱ genes,and other genes,namely MHC class Ⅲ genes tumor necrosis factor(TNF)-α and-β,and Hsp,whose proteins play key functions in immunological processes.To date,it is not clear which genes within the MHC family contribute to the IBD pathogenesis,although certain HLA alleles have been associated with IBD.Recent insights into the biological function of other genes encoded within the IBD3 region,such as the MHC class Ⅰ chain-related(MIC) genes,have led investigators to a more comprehensive exploration of this region.MHC class Ⅰ chain-related molecule A(MICA) is highly polymorphic and interacts with NKG2 D,its receptor on the surface of NK,Tγδ and T CD8+ cells.Increased expression of MICA in intestinal epithelial cells and increased expression of NKG2 D in CD4+ T cells(lamina propria) in patients with CD have also been reported.MICA alleles have also been associated with IBD,and a variation at amino acid position 129 of the α2-heavy chain domain seems to categorize MICA alleles into strong and weak binders of NKG2 D receptor,thereby influencing the effector cells' function.In this regard,a relevant role of MICA-129-Val/Met single nucleotide polymorphism has recently been implicated in the pathogenesis of IBD.TNF-α and-β also play an important role in inflammatory response.In fact,IBD is commonly treated with TNF-α inhibitors.Additionally,polymorphisms of TNF-α gene are known to affect the gene expression level and particular TNF-α genotypes may influence the response of IBD patients treated with TNF-α inhibitors. | Manuel Muro Ruth López-Hernández Anna Mrowiec | 2014 | World Journal of Gastroenterology2014，20，41： | 6 |
| 4 | 膨胀石墨吸油特性的研究显示文摘通过对不同形态和填充密度的膨胀石墨(EG)进行的毛细吸附实验,着重研究了EG的比表面积和填充密度对吸油特性的影响.实验结果表明:细颗粒状EG样品的比表面积从0 624m2/g到34 20m2/g显著变化时,对柴油吸附率的改善并不显著;与细颗粒状EG样品相比,大颗粒蠕虫状样品具有更高的吸附率;填充密度的变化对A级重油吸附率有显著影响. | 陈跃军 Shoji Muro Jǖrgen Walter 戴光泽 | 2003 | 西南交通大学学报2003，38，6： | 6 |
| 5 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer显示文摘 | Yoon-Koo Kang Kei Muro Min-Hee Ryu Hirofumi Yasui Tomohiro Nishina Baek-Yeol Ryoo Yukimasa Kamiya Shiro Akinaga Narikazu Boku | 2014 | Investigational New Drugs2014，，2： | 5 |
| 6 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer显示文摘 | Toshiaki Watanabe Michio Itabashi Yasuhiro Shimada Shinji Tanaka Yoshinori Ito Yoichi Ajioka Tetsuya Hamaguchi Ichinosuke Hyodo Masahiro Igarashi Hideyuki Ishida Megumi Ishiguro Yukihide Kanemitsu Norihiro Kokudo Kei Muro Atsushi Ochiai Masahiko Oguchi Ya | 2012 | International Journal of Clinical Oncology2012，，1： | 5 |
| 7 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial显示文摘 | Hansjochen Wilke Kei Muro Eric Van Cutsem Sang-Cheul Oh Gy?rgy Bodoky Yasuhiro Shimada Shuichi Hironaka Naotoshi Sugimoto Oleg Lipatov Tae-You Kim David Cunningham Philippe Rougier Yoshito Komatsu Jaffer Ajani Michael Emig Roberto Carlesi David Ferry Kuma | 2014 | Lancet Oncology2014，，11： | 4 |
| 8 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 9 | Efficacy of Endoscopic Over 3-branched Partial Stent-in-Stent Drainage Using Self-expandable Metallic Stents in Patients With Unresectable Hilar Biliary Carcinoma显示文摘 | Daisuke Uchida Hironari Kato Shinichiro Muro Yasuhiro Noma Naoki Yamamoto Shigeru Horiguchi Ryo Harada Koichiro Tsutsumi Hirofumi Kawamoto Hiroyuki Okada Kazuhide Yamamoto | 2015 | Journal of Clinical Gastroenterology2015，，6： | 2 |
| 10 | Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer显示文摘 | Yasutsuna Sasaki Tomohiro Nishina Hirofumi Yasui Masahiro Goto Kei Muro Akihito Tsuji Wasaburo Koizumi Yasushi Toh Takuo Hara Yoshinori Miyata | 2014 | Cancer Sci2014，，7： | 2 |
| 11 | Prediction of contractile reserve by cyclic variation of integrated backscatter of the myocardium in patients with chronic left ventricular dysfunction显示文摘 | MURO T OTA T WATANABE H | 2001 | Heart2001，85，2： | 2 |
| 12 | Discrpancies in HLA-C typing in transplantation: comparison of PCR-SSP and serology result显示文摘 | Torio MA Muro MO Ontonon JA | 2002 | Trans Proc2002，34，： | 2 |
| 13 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) 显示文摘 | Muro K Boku N Shimada Y | 2010 | Lancet Oneol2010，11，9： | 1 |
| 14 | Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation显示文摘 | Terada K Muro S Sato S | 2008 | Thorax2008，63，11： | 1 |
| 15 | Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy显示文摘 | Navarro-GonzalezJF Mora-Fernandez C Muros de Fuentes M | 2011 | Nat Rev Nephrol2011，7，6： | 1 |
| 16 | Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy显示文摘 | Navarro-Gonzdlez J F Mora-Ferndndez C Muros de Fuentes M Garcia-Perez J | 2011 | Nat Rev Nephrol2011，7，： | 1 |
| 17 | HLA- DRB1And HIA -DQB1 genes on susceptibility to and protection from allergic bronchopulmonary asper- gillosis in patients with cystic fibrosis显示文摘 | Muro M Mondejar- Lopez P Moya- Quiles MR | 2013 | Microbiol Im- munol2013，57，3： | 1 |
| 18 | Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients显示文摘 | Navarro JF Mora C Muros M | 2006 | Nephrol Dial Transplant2006，21，12： | 1 |
| 19 | New freeze-drying method for synthesis 显示文摘 | Palomares V Goni A Muro I G | 2007 | J Power Sources2007，171，： | 1 |
| 20 | Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions显示文摘 | Ochs RL Muro Y Si Y | 2000 | J Allergy Clin Immunol2000，105，61： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员